Related Experiment Video
Updated: Jan 28, 2026

Enrichment of Bacterial Lipoproteins and Preparation of N-terminal Lipopeptides for Structural Determination by Mass Spectrometry
Published on: May 21, 2018
Lipoprotein(a): structural basis, bidirectional risk, and therapeutic frontiers
Zeyu Xu1, Yi Fang1, Yong Peng1
1The Third Affiliated Hospital of Nanchang University, 128 Xiangshan North Road, Donghu District, Nanchang City, Jiangxi Province, 330008, China.
Insights
Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular disease risk factor. This review explores Lp(a) structure, genetics, and emerging therapies for managing its levels.
Area of Science:
- Cardiovascular Science
- Genetics
- Biochemistry
Background:
- Cardiovascular disease (CVD) management has advanced, yet lipoprotein(a) [Lp(a)] remains an under-recognized genetic risk factor.
- Both very high and very low Lp(a) levels are associated with adverse health outcomes.
- Current Lp(a) diagnostics lack standardization, and existing lipid-lowering therapies have minimal impact on Lp(a) levels, limiting treatment options.
Purpose of the Study:
- To provide a comprehensive molecular and clinical review of lipoprotein(a) [Lp(a)].
- To examine Lp(a)'s structure, genetic determinants, metabolism, and factors affecting plasma concentration.
- To discuss novel therapeutic strategies targeting Lp(a).
Main Methods:
- Comprehensive literature review.
- Analysis of molecular and clinical data.
- Synthesis of current knowledge on Lp(a) biology and therapeutics.
Main Results:
- Lp(a) has a unique structure and is influenced by genetic factors and metabolic pathways.
- Plasma concentrations of Lp(a) are affected by various biological and environmental factors.
- Emerging therapies show promise for specifically targeting Lp(a).
Conclusions:
- Lipoprotein(a) [Lp(a)] represents a significant, genetically determined risk factor for cardiovascular disease.
- Addressing diagnostic and therapeutic challenges for Lp(a) is crucial for improving patient outcomes.
- Further research into Lp(a) biology and targeted therapies is warranted.
Abstract:
Despite substantial progress in the management of cardiovascular disease (CVD), lipoprotein(a) [Lp(a)] persists as a genetically determined risk factor that remains insufficiently explored. Both extremely high and low levels of Lp(a) are linked to adverse outcomes. Current diagnostic assays for Lp(a) lack standardization, and conventional lipid-lowering therapies exert minimal effects on its levels, resulting in limited treatment options specifically targeting Lp(a). To address these gaps, we conducted a comprehensive molecular and clinical review of Lp(a), examining its unique structure, genetic determinants, metabolic pathways, and the factors influencing its plasma concentration. Furthermore, we discuss emerging therapeutic strategies aimed at targeting Lp(a).
Related Concept Videos
Structures of Solids
Relative Risk
Therapeutic Index
RNA Structure
The basic structure of RNA consists of a five-carbon sugar and one of four nitrogenous bases. Although most RNA is single-stranded, it can form complex secondary and tertiary structures. Such structures play essential roles in the regulation of transcription and translation.
Different Types of RNA Have the Same Basic Structure
There are three main types of ribonucleic acid (RNA): messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). All three RNA types consist of a...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...

